FibroBiologics Inc. has announced that it has fully repaid all outstanding amounts under its convertible promissory notes previously issued to YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global. The repayment eliminates further dilution from potential conversions of these notes into common stock. With the debt now cleared, FibroBiologics' balance sheet is strengthened, allowing the company to focus on advancing its clinical programs. The Standby Equity Purchase Agreement with Yorkville remains in place, permitting the company to sell up to an additional $10 million of its common stock at its discretion through December 2026, subject to certain conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9592541-en) on November 26, 2025, and is solely responsible for the information contained therein.